[1] Venables ZC, Autier P, Nijsten T, et al.Nationwide Incidenceof Metastatic Cutaneous Squamous Cell Carcinoma in England[J]JAMA Dermatol, 2018, 155(3):298-306. [2] Migden MR, Rischin D, Schmults CD, et al.PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma[J].N Engl J Med, 2018, 379(4):341-351. [3] Markham A, Duggan S.Cemiplimab: First Global Approval[J].Drugs, 2018, 78(17):1841-1846. [4] Sidaway P.Cemiplimab effective in cutaneous SCC[J]. Nat Rev Clin Oncol, 2018, 15(8):472. [5] U.S. Food and Drug Administration. Questions and Answers on FDA's Adverse Event Reporting System (FAERS) [EB/OL]. (2019-08-12)[2019-12-01]. https://www.fda.gov/drugs/surveillance/fda-adverse-event-reporting-system-faers. [6] Medical Dictionary for Regulatory Activities. Support Documen-tation: MedDRA Version 22.0 English March2019[EB/OL]. (2019-03-01)[2019-12-01]. https://www.meddra.org/how-to-use/support-documentation. [7] Van Puijenbroek EP, Bate A, Leufkens HG, et al.A comparisonof measures of disproportionality for signal detection inspontaneousreporting systems for adverse drug reactions[J].Pharmacoepidemiol Drug Saf, 2002, 11(1):3-10. [8] Bate A, Lindquist M, Edwards IR, et al.A Bayesian neuralnetwork method for adverse drug reaction signal generation[J].Eur J Clin Pharmacol, 1998(54):315-321. [9] Noren GN, Hopstadius J, Bate A.Shrinkage observed-to-expectedratios for robust and transparent large-scale pattern discovery[J].Stat Methods Med Res, 2013(22):57-69. [10] Frenel JS, Le Tourneau C, O'Neil B, et al. Safety and Efficacy ofPembrolizumab in Advanced, Programmed Death Ligand 1-PositiveCervical Cancer: Results From the Phase Ib KEYNOTE-028Trial[J]. J Clin Oncol, 2017, 35(36):4035-4041. [11] Younes A, Santoro A, Shipp M, et al.Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort,single-arm phase 2 trial[J]. Lancet Oncol, 2016, 17(9):1283-1294. [12] Oda H, Ishihara M, Miyahara Y, et al.First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer[J]. Case Rep Oncol, 2019, 12(1):147-156. [13] Sindel A, Taylor T, Chesney A, et al.Hematopoietic stem cell mobilization following PD-1 blockade: Cytokine release syndrome after transplantation managed with ascorbic acid[J]. Eur J Haem- atol, 2019, 103(2):134-136. [14] Honjo O, Kubo T, Sugaya F, et al.Severe cytokine release syndrome resulting in purpura fulminans despite successful response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case report[J]. J Immunother Cancer, 2019, 7(1):97. [15] Ueno M, Ikeda M, Morizane C, et al.Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-rand-omised, multicentre, open-label, phase 1 study[J]. LancetGastroenterol Hepatol, 2019, 4(8):611-621. [16] Barbacki A, Maliha PG, Hudson M, et al.A case of severe Pemb-rolizumab-induced neutropenia[J]. Anticancer Drugs, 2018, 29(8):817-819. [17] Petrelli F, Ardito R, Borgonovo K, et al.Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis[J]. Eur J Cancer, 2018(103):7-16. [18] Delanoy N, Michot JM, Comont T, et al.Haematological immune- related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study[J]. Lancet Haematol, 2019, 6(1): 48-57. [19] Naqash AR, Appah E, Yang LV, et al.Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition[J]. J Immunother Cancer, 2019, 7(1):169. [20] Liao JP, Nie LG, Que CL, et al.Severe Pneumonitis after Nivol-umab Treatment Accompanied by Acute Pulmonary Embolism in a Patient with Lung Adenocarcinoma[J]. Chin Med J (Engl),2017, 130(22):2755-2756. [21] Brahmer JR, Lacchetti C, Schneider BJ, et al.Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018,36(17):1714-1768. |